175204-38-3

Usage

Uses

Used in Pharmaceutical Industry:
[3-(2,6-DICHLOROPHENYL)-5-METHYLISOXAZOL-4-YL]METHANOL is used as a potential active pharmaceutical ingredient for its unique molecular structure that may interact with biological targets, offering new avenues for drug discovery and development. Its specific properties, such as the presence of chlorine atoms and a heterocyclic ring, could be leveraged to create novel therapeutic agents.
Used in Agrochemical Industry:
In the agrochemical sector, [3-(2,6-DICHLOROPHENYL)-5-METHYLISOXAZOL-4-YL]METHANOL may serve as a precursor or intermediate in the synthesis of new pesticides or herbicides. Its chemical structure could provide specific modes of action against pests or weeds, contributing to more effective and targeted agricultural solutions.
Used in Chemical Research:
[3-(2,6-DICHLOROPHENYL)-5-METHYLISOXAZOL-4-YL]METHANOL is utilized as a subject of chemical research to explore its reactivity, stability, and potential to form new compounds. Understanding its behavior in various chemical reactions can lead to the discovery of new materials or processes with applications across different industries.
Further research and testing are essential to fully comprehend the uses and effects of [3-(2,6-DICHLOROPHENYL)-5-METHYLISOXAZOL-4-YL]METHANOL, ensuring its safe and effective application in the intended fields.

InChI:InChI=1/C11H9Cl2NO2/c1-6-7(5-15)11(14-16-6)10-8(12)3-2-4-9(10)13/h2-4,15H,5H2,1H3

Upstream product

• 3919-76-4 3-(2,6-dichloro-phenyl)-5-methyl-isoxazole-4-carboxylic acid 
• 83-38-5 2,6-dichlorobenzaldehyde 
• 6575-28-6 (1E)-2,6-dichlorobenzaldehyde oxime 
• 6579-27-7 2,6-Dichloro-N-hydroxybenzenecarboximidoyl chloride 
• 4402-83-9 SPB 06193 

Downstream Products

• 303225-22-1 4-(chloromethyl)-3-(2,6-dichlorophenyl)-5-methylisoxazole 
• 287176-81-2 4-(bromomethyl)-3-(2,6-dichlorophenyl)-5-methylisoxazole 
• 919285-21-5 (4-{2-[3-(2,6-dichloro-phenyl)-5-methyl-isoxazol-4-ylmethoxy]-ethoxy}-2-methyl-phenoxy)-acetic acid methyl ester 
• 870194-46-0 2-[3-(2,6-dichloro-phenyl)-5-methyl-isoxazol-4-ylmethoxy]-ethanol 

Relevant academic research and scientific papers

COMPOUNDS FOR MODULATING FXR

Provided herein are compounds of Formula (I), a stereoisomer, enantiomer or a pharmaceutically acceptable salt thereof; wherein variables are as defined herein; and their pharmaceutical compositions, which are useful as modulators of the activity of Farnesoid X receptors (FXR).

Design, Synthesis, and Biological Evaluation of Novel Nonsteroidal Farnesoid X Receptor (FXR) Antagonists: Molecular Basis of FXR Antagonism

Farnesoid X receptor (FXR) plays an important role in the regulation of cholesterol, lipid, and glucose metabolism. Recently, several studies on the molecular basis of FXR antagonism have been reported. However, none of these studies employs an FXR antagonist with nonsteroidal scaffold. On the basis of our previously reported FXR antagonist with a trisubstituted isoxazole scaffold, a novel nonsteroidal FXR ligand was designed and used as a lead for structural modification. In total, 39 new trisubstituted isoxazole derivatives were designed and synthesized, which led to pharmacological profiles ranging from agonist to antagonist toward FXR. Notably, compound 5s (4′-[(3-{[3-(2-chlorophenyl)-5-(2-thienyl)isoxazol-4-yl]methoxy}-1H-pyrazol-1-yl)methyl]biphenyl-2-carboxylic acid), containing a thienyl-substituted isoxazole ring, displayed the best antagonistic activity against FXR with good cellular potency (IC50=12.2±0.2μM). Eventually, this compound was used as a probe in a molecular dynamics simulation assay. Our results allowed us to propose an essential molecular basis for FXR antagonism, which is consistent with a previously reported antagonistic mechanism; furthermore, E467 on H12 was found to be a hot-spot residue and may be important for the future design of nonsteroidal antagonists of FXR. X marks the spot: 39 trisubstituted isoxazoles were designed and synthesized, leading to compounds with pharmacological profiles ranging from agonist to antagonist at the farnesoid X receptor (FXR). By using the most potent antagonist as a probe, the essential molecular basis of FXR antagonism is proposed, and E467 on H12 can be regarded as a hot-spot residue for the future design of nonsteroidal antagonists of FXR.

3,4,5-Trisubstituted isoxazoles as novel PPARδ agonists: Part 1

We report the identification of a novel series of trisubstituted isoxazoles as PPAR activators from a high-throughput screen. A series of structural optimizations led to improved efficacy and excellent functional receptor selectivity for PPARδ. The isoxazoles represent a series of agonists which display a scaffold that lies outside the typical PPAR agonist motif.

COMPOUNDS AND COMPOSITIONS AS PPAR MODULATORS

The invention provides compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with the activity of the Peroxisome Proliferator-Activated Receptor (PPAR) families, particularly the activity of PPAR .